Link Begins First Human Test of Dual Antigen CAR T

Company Link Cell Therapies Event Type Phase 1 Initiation Modality Logic-Gated (AND-Gate) CAR-T Asset LNK001 Target CAIX and ENPP3 (Dual Antigen) Disease Area Advanced Clear-Cell Renal Cell Carcinoma Summary Link Cell Therapies initiated clinical dosing of LNK001, an autologous logic-gated CAR-T therapy that requires coexpression…